NASDAQ: IMRXImmuneering Corp Stock
$2.45-0.02 (-0.81%)
Updated Oct 7, 2024
IMRX Price
$2.45
Fair Value Price
$1.93
Market Cap
$72.65M
52 Week Low
$1.00
52 Week High
$8.89
P/E
-1.28x
P/B
1.1x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$56.07M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.16
Operating Cash Flow
-$51M
Beta
1.4
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IMRX Overview
Immuneering Corporation is a a biopharma focused on the oncology and neuroscience sectors. The company's oncology programs is developing treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Its lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Immuneering was incorporated in 2008 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMRX ($2.45) is overvalued by 26.71% relative to our estimate of its Fair Value price of $1.93 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMRX ($2.45) is not significantly undervalued (26.71%) relative to our estimate of its Fair Value price of $1.93 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMRX due diligence checks available for Premium users.
Be the first to know about important IMRX news, forecast changes, insider trades & much more!
IMRX News
Valuation
IMRX fair value
Fair Value of IMRX stock based on Discounted Cash Flow (DCF)
Price
$2.45
Fair Value
$1.93
Overvalued by
26.71%
IMRX ($2.45) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMRX ($2.45) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.28x
Industry
-111.33x
Market
26.63x
IMRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.1x
Industry
5.95x
IMRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.1M
Profit Margin
0%
IMRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$77.1M
Liabilities
$10.8M
Debt to equity
0.16
IMRX's short-term assets ($63.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMRX's short-term assets ($63.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.5M
Investing
$5.0M
Financing
$0.0
IMRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMRX vs Biotech Stocks
Immuneering Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.